Antifungal Prophylaxis in Cancer Patients

Rod Quilitz, Pharm.D., BCOP
Friday, June 6, 2014
Category: Infectious in Oncology, Mould Infections

Rod Quilitz, PharmD, speaks about antifungal prophylaxis in cancer patients. Since these patients are largely immunocompromised, they are more susceptible to fungal infections, both by irritating manifestations like mucocutaneous candidiasis and potentially life-threatening invasive systemic fungal infections. However, antifungal medications can cause toxicity and drug interactions that must be balanced with the risk of infection in these patients. He covers candidiasis and aspergillosis, and the agents used to treat and prevent them. He also covers contraindications to antifungal prophylaxis.

Stay in touch! Download our app in the iTunes store or the Google Marketplace.